Our Vision

To uncover immune signatures to assess the health of an individual in support of personalized and precision medicine.

About SLE-key™

- ImmunArray’s first commercial iCHIP™ product is the SLE-key™ SLE rule-out test.
- The SLE-key™ test profiles the immune system as a whole to gain insight into states of health and disease by analyzing a broad array of autoantibodies via a proprietary microarray of corresponding antigens.
- Objective data obtained from the SLE-key™ can be analyzed from a single time point or on a relative basis over time to monitor change in disease state and/or response to therapy.

About Test Results

- Results have categorized a patient as manifesting a pattern not consistent with SLE with > 90% sensitivity and > 70% specificity, thus excluding SLE during the differential diagnosis.

Healthy

SLE Affected

SLE patient profiles are distinct from the profiles of healthy individuals.

For Doctors

Provided via our service lab

Visit us at www.sle-key.com

ImmunArray’s first commercial iCHIP™ product is the SLE-key™ SLE rule-out test.

The SLE-key™ test profiles the immune system as a whole to gain insight into states of health and disease by analyzing a broad array of autoantibodies via a proprietary microarray of corresponding antigens.

Objective data obtained from the SLE-key™ can be analyzed from a single time point or on a relative basis over time to monitor change in disease state and/or response to therapy.

Results have categorized a patient as manifesting a pattern not consistent with SLE with > 90% sensitivity and > 70% specificity, thus excluding SLE during the differential diagnosis.

SLE patient profiles are distinct from the profiles of healthy individuals.
It is estimated that 5 million people throughout the world have a form of lupus.

It is estimated that as many as 1.5 million Americans have lupus with SLE being the most common form.

More than 16,000 new cases of lupus are reported annually in the United States.

A Lupus Foundation of America survey suggests that more than half of those afflicted with lupus waited at least four years and saw three or more doctors before obtaining a correct diagnosis.

Lupus is rare; worrying about lupus is not. Conventional tests used today routinely lead to a high rate of false positive results, or an incorrect finding, when initially diagnosing SLE.

The iCHIP™ is a microarray which is manufactured using nano-printing technology to delineate informative patterns or signatures of autoantibodies.

The iCHIP™ technology is a flexible and readily customizable tool that provides a detailed view across the immune system.

**iCHIP™ Technology Platform**  
*A proprietary microarray of antigens*

- Stable platform with 100s of antigens
- Rapid identification of disease-specific immune signatures
- Allows isotyping

**iCHIP™ Products**  
*A custom application of technology*

- Disease- or product-specific antigen arrays
- Carries variable numbers of antigens (5-100)
- Highly sensitive (detection of antibodies)
- Directly applicable in our service laboratory

**Immunology Review**

**Microarray Technology**

**SLE**

* Please visit the full list of our publications at [http://www.sle-key/publications](http://www.sle-key/publications)